دورية أكاديمية
أعرض في EDS

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.

التفاصيل البيبلوغرافية
العنوان: Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
المؤلفون: Wu S; University of California, San Diego, La Jolla, CA., Hoang HB; University of California, San Diego, La Jolla, CA., Yang JZ; University of California, San Diego, La Jolla, CA., Papamatheakis DG; University of California, San Diego, La Jolla, CA., Poch DS; University of California, San Diego, La Jolla, CA., Alotaibi M; University of California, San Diego, La Jolla, CA., Lombardi S; University of California, San Diego, La Jolla, CA., Rodriguez C; University of California, San Diego, La Jolla, CA., Kim NH; University of California, San Diego, La Jolla, CA., Fernandes TM; University of California, San Diego, La Jolla, CA. Electronic address: tfernandes@health.ucsd.edu.
المصدر: Chest [Chest] 2022 Dec; Vol. 162 (6), pp. 1360-1372. Date of Electronic Publication: 2022 Jul 14.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0231335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-3543 (Electronic) Linking ISSN: 00123692 NLM ISO Abbreviation: Chest Subsets: MEDLINE
أسماء مطبوعة: Publication: 2016- : New York : Elsevier
Original Publication: Chicago : American College of Chest Physicians
مواضيع طبية MeSH: Pulmonary Arterial Hypertension*/drug therapy , Hypertension, Pulmonary*, Humans ; Familial Primary Pulmonary Hypertension/complications ; Bosentan/therapeutic use ; Drug Interactions ; Antihypertensive Agents/therapeutic use
مستخلص: The management of pulmonary arterial hypertension (PAH) has become more complex in recent years because of increased pharmacotherapy options and longer patient survival with increasing numbers of comorbidities. As such, more opportunities exist for drug-drug interactions between PAH-targeted medications and medications potentially used to treat comorbid conditions. In this review, we provide an overview of pharmaceutical metabolism by cytochrome P450 and discuss important drug-drug interactions for the 14 Food and Drug Administration-approved medications for PAH in the nitric oxide (NO), endothelin, and prostacyclin pathways. Among the targets in the NO pathway (sildenafil, tadalafil, and riociguat), important interactions with nitrates, protease inhibitors, and other phosphodiesterase inhibitors can cause profound hypotension. In the endothelin pathway, bosentan is associated with more drug interactions via CYP3A4 inhibition; macitentan and ambrisentan have fewer interactions of note. Although the parenteral therapies in the prostacyclin pathway bypass significant liver metabolism and avoid drug interactions, selexipag and oral treprostinil may exhibit interactions with CYP2C8 inhibitors such as gemfibrozil and clopidogrel, which can raise drug levels. Finally, we provide a framework for identifying potential drug-drug interactions and avoiding errors.
(Published by Elsevier Inc.)
References: Br J Clin Pharmacol. 2021 Jan;87(1):119-128. (PMID: 32415684)
Expert Opin Drug Saf. 2014 Mar;13(3):391-405. (PMID: 24261583)
Eur Respir J. 2018 May 3;51(5):. (PMID: 29622568)
Eur Heart J. 2016 Jan 1;37(1):67-119. (PMID: 26320113)
Circulation. 2010 Jul 6;122(1):88-95. (PMID: 20606131)
BMJ. 2000 Mar 18;320(7237):768-70. (PMID: 10720363)
P T. 2014 Nov;39(11):749-58. (PMID: 25395817)
Hypertension. 1996 Jul;28(1):109-14. (PMID: 8675249)
Eur Respir J. 2015 Aug;46(2):405-13. (PMID: 26113687)
AAPS J. 2012 Mar;14(1):68-78. (PMID: 22189899)
J Clin Pharmacol. 2005 Jan;45(1):68-78. (PMID: 15601807)
J Clin Pharmacol. 2012 Dec;52(12):1784-805. (PMID: 22205719)
J Clin Med. 2020 Mar 18;9(3):. (PMID: 32197449)
J Clin Pharmacol. 2005 Sep;45(9):987-1003. (PMID: 16100293)
Clin Pharmacol Ther. 2002 Apr;71(4):253-62. (PMID: 11956508)
Biol Pharm Bull. 2015;38(1):58-65. (PMID: 25744459)
Ann Pharmacother. 2017 Nov;51(11):1008-1022. (PMID: 28627229)
Chest. 2010 Feb;137(2):376-87. (PMID: 19837821)
Br J Clin Pharmacol. 2017 Dec;83(12):2778-2788. (PMID: 28715853)
Drug Saf. 2005;28(9):789-801. (PMID: 16119972)
J Antimicrob Chemother. 2016 Jul;71(7):1755-8. (PMID: 26945713)
Ther Adv Respir Dis. 2012 Dec;6(6):331-43. (PMID: 22933513)
Pharmacol Rev. 2016 Jan;68(1):168-241. (PMID: 26721703)
J Thorac Dis. 2019 Sep;11(Suppl 14):S1767-S1781. (PMID: 31632754)
Am J Hypertens. 2001 Jan;14(1):70-3. (PMID: 11206684)
Drug Metab Dispos. 2000 Apr;28(4):392-7. (PMID: 10725306)
Lancet. 1987 Nov 7;2(8567):1057-8. (PMID: 2889967)
N Engl J Med. 2013 Dec 5;369(23):2268. (PMID: 24304056)
Glob Cardiol Sci Pract. 2014 Dec 31;2014(4):382-93. (PMID: 25780793)
Int J Mol Sci. 2021 May 13;22(10):. (PMID: 34067981)
Ann Intern Med. 1987 Aug;107(2):216-23. (PMID: 3605900)
Eur Respir J. 2015 May;45(5):1314-22. (PMID: 25657022)
J Adv Pract Oncol. 2013 Jul;4(4):263-8. (PMID: 25032007)
N Engl J Med. 2021 Dec 16;385(25):2361-2376. (PMID: 34910865)
Clin Pharmacokinet. 2013 Aug;52(8):685-92. (PMID: 23568224)
Clin Drug Investig. 2010;30(12):875-885. (PMID: 20923245)
Clin Pharmacokinet. 2016 May;55(5):615-24. (PMID: 26507720)
Annu Rev Pharmacol Toxicol. 2007;47:731-59. (PMID: 17002597)
Am J Cardiol. 2003 Nov 6;92(9A):47M-57M. (PMID: 14609623)
Drug Metab Dispos. 2003 Dec;31(12):1461-73. (PMID: 14625342)
Drug Metab Dispos. 2000 Feb;28(2):125-30. (PMID: 10640508)
Am Fam Physician. 2007 Aug 1;76(3):391-6. (PMID: 17708140)
فهرسة مساهمة: Keywords: PAH; cytochrome P450; drug interactions; pulmonary arterial hypertension
المشرفين على المادة: Q326023R30 (Bosentan)
0 (Antihypertensive Agents)
تواريخ الأحداث: Date Created: 20220716 Date Completed: 20221216 Latest Revision: 20230104
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9773230
DOI: 10.1016/j.chest.2022.06.042
PMID: 35841932
قاعدة البيانات: MEDLINE
الوصف
تدمد:1931-3543
DOI:10.1016/j.chest.2022.06.042